Clinical Trials
14 trialsNCT02836548 2025-07-10
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT03110159 2024-03-15
DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients
Medical Dermatology Specialists
Phase 1/2 Completed
NCT00019188 2024-03-04
Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT03602079 2023-08-03
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Phase 1/2 Completed
NCT03989115 2023-06-26
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Phase 1/2 Completed
NCT00520299 2022-10-25
Study of ADI-PEG 20 in Patients With Advanced Melanoma
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT01861496 2022-02-24
LiPlaCis
Allarity Therapeutics
Phase 1/2 Completed
NCT00333502 2020-05-28
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
Lumos Pharma
Phase 1/2 Completed
NCT01791894 2018-06-08
ATO
Stanford University
Phase 1/2 Completed
NCT02550678 2018-06-06
ASN-002-001
Ascend Biopharmaceuticals Ltd
Phase 1/2 Completed
NCT01079741 2018-02-13
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT00847522 2017-12-20
Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma
University of Utah
Phase 1/2 Completed
NCT00715793 2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2 Completed
NCT00403377 2015-10-01
Investigation of a Behavioral Substitute for Sunbathing
University of Massachusetts, Worcester
Phase 1/2 Completed